Chem Shift validation: AVS_full
BMRB Entry DOI: doi:10.13018/BMR51921
NMR-STAR file interactive viewer.
NMR-STAR v3 text file.
XML gzip file.
RDF gzip file.
All files associated with the entry
Citation: Bumbak, Fabian; Bower, James; Zemmer, Skylar; Inoue, Asuka; Pons, Miquel; Paniagua, Juan Carlos; Yan, Fei; Ford, James; Wu, Hongwei; Robson, Scott; Bathgate, Ross; Scott, Daniel; Gooley, Paul; Ziarek, Joshua. "Stabilization of pre-existing neurotensin receptor conformational states by b-arrestin-1 and the biased allosteric modulator ML314" Nat. commun. 14, 3328-3328 (2023).
PubMed: 37286565
Assembly members:
entity_1, polymer, 404 residues, 44889.10 Da.
entity_2, polymer, 6 residues, 817 Da.
entity_3, polymer, 357 residues, 40611.26 Da.
entity_4, non-polymer, Formula weight is not available
Natural source: Common Name: Rat Taxonomy ID: 10116 Superkingdom: Eukaryota Kingdom: Metazoa Genus/species: Rattus norvegicus
Experimental source: Production method: recombinant technology Host organism: Escherichia coli Vector: pDS170
Entity Sequences (FASTA):
entity_1: GPGSTSESDTAGPNSDLDVN
TDIYSKVLVTAIYLALFVVG
TVGNGVTLFTLARKKSLQSL
QSRVDYYLGSLALSSLLILL
FALPVDVYNFIWVHHPWAFG
DAGCKGYYFLREACTYATAL
NVVSLSVERYLAICHPFKAK
TLLSRSRTKKFISAIWLASA
LLSLPMLFTMGLQNLSGDGT
HPGGLVCTPIVDTATLRVVI
QLNTFMSFLFPMLVASILNT
VIARRLTVLVHQAAEQARVS
TVGTHNGLEHSTFNVTIEPG
RVQALRRGVLVLRAVVIAFV
VCWLPYHVRRLMFVYISDEQ
WTTALFDFYHYFYMLSNALV
YVSAAINPILYNLVSANFRQ
VFLSTLASLSPGWRHRRKKR
PTFSRKPNSVSSNHAFSTAS
GLNDIFEAQKIEWHEGSGLE
VLFQ
entity_2: RRPYIL
entity_3: GPGSGCTLSAEDKAAVERSK
MIDRNLREDGEKAAREVKLL
LLGAGESGKSTIVKQMKIIH
EAGYSEEECKQYKAVVYSNT
IQSIIAIIRAMGRLKIDFGD
SARADDARQLFVLAGAAEEG
FMTAELAGVIKRLWKDSGVQ
ACFNRSREYQLNDSAAYYLN
DLDRIAQPNYIPTQQDVLRT
RVKTTGIVETHFTFKDLHFK
MFDVGGQRSERKKWIHCFEG
VTAIIFCVALSDYDLVLAED
EEMNRMHESMKLFDSICNNK
WFTDTSIILFLNKKDLFEEK
IKKSPLTICYPEYAGSNTYE
EAAAYIQCQFEDLNKRKDTK
EIYTHFTCATDTKNVQFVFD
AVTDVIIKNNLKEYNLV
Data type | Count |
13C chemical shifts | 11 |
1H chemical shifts | 33 |
Entity Assembly ID | Entity Name | Entity ID |
---|---|---|
1 | enNTS1DM4, conformer A | 1 |
2 | enNTS1DM4, conformer B | 1 |
3 | enNTS1DM4, conformer C | 1 |
4 | enNTS1DM4, conformer D | 1 |
5 | enNTS1DM4, conformer E | 1 |
6 | NT8-13 | 2 |
7 | Gaiq | 3 |
8 | PIP2 | 4 |
Entity 1, enNTS1DM4, conformer A 404 residues - 44889.10 Da.
Thermostabilized rat neurotensin receptor 1 variant starts with the first T (T43) and ends with T416 (truncated). The protein contains a C-terminal Avi-tag and remnants of a 3C-protease cleavage tag (ASGLNDIFEAQKIEWHEGSGLEVLFQ). The N-terminal four residues (GPGS) are remnants of a 3C-protease cleavage site and a short, flexible GS sequence.
1 | GLY | PRO | GLY | SER | THR | SER | GLU | SER | ASP | THR | ||||
2 | ALA | GLY | PRO | ASN | SER | ASP | LEU | ASP | VAL | ASN | ||||
3 | THR | ASP | ILE | TYR | SER | LYS | VAL | LEU | VAL | THR | ||||
4 | ALA | ILE | TYR | LEU | ALA | LEU | PHE | VAL | VAL | GLY | ||||
5 | THR | VAL | GLY | ASN | GLY | VAL | THR | LEU | PHE | THR | ||||
6 | LEU | ALA | ARG | LYS | LYS | SER | LEU | GLN | SER | LEU | ||||
7 | GLN | SER | ARG | VAL | ASP | TYR | TYR | LEU | GLY | SER | ||||
8 | LEU | ALA | LEU | SER | SER | LEU | LEU | ILE | LEU | LEU | ||||
9 | PHE | ALA | LEU | PRO | VAL | ASP | VAL | TYR | ASN | PHE | ||||
10 | ILE | TRP | VAL | HIS | HIS | PRO | TRP | ALA | PHE | GLY | ||||
11 | ASP | ALA | GLY | CYS | LYS | GLY | TYR | TYR | PHE | LEU | ||||
12 | ARG | GLU | ALA | CYS | THR | TYR | ALA | THR | ALA | LEU | ||||
13 | ASN | VAL | VAL | SER | LEU | SER | VAL | GLU | ARG | TYR | ||||
14 | LEU | ALA | ILE | CYS | HIS | PRO | PHE | LYS | ALA | LYS | ||||
15 | THR | LEU | LEU | SER | ARG | SER | ARG | THR | LYS | LYS | ||||
16 | PHE | ILE | SER | ALA | ILE | TRP | LEU | ALA | SER | ALA | ||||
17 | LEU | LEU | SER | LEU | PRO | MET | LEU | PHE | THR | MET | ||||
18 | GLY | LEU | GLN | ASN | LEU | SER | GLY | ASP | GLY | THR | ||||
19 | HIS | PRO | GLY | GLY | LEU | VAL | CYS | THR | PRO | ILE | ||||
20 | VAL | ASP | THR | ALA | THR | LEU | ARG | VAL | VAL | ILE | ||||
21 | GLN | LEU | ASN | THR | PHE | MET | SER | PHE | LEU | PHE | ||||
22 | PRO | MET | LEU | VAL | ALA | SER | ILE | LEU | ASN | THR | ||||
23 | VAL | ILE | ALA | ARG | ARG | LEU | THR | VAL | LEU | VAL | ||||
24 | HIS | GLN | ALA | ALA | GLU | GLN | ALA | ARG | VAL | SER | ||||
25 | THR | VAL | GLY | THR | HIS | ASN | GLY | LEU | GLU | HIS | ||||
26 | SER | THR | PHE | ASN | VAL | THR | ILE | GLU | PRO | GLY | ||||
27 | ARG | VAL | GLN | ALA | LEU | ARG | ARG | GLY | VAL | LEU | ||||
28 | VAL | LEU | ARG | ALA | VAL | VAL | ILE | ALA | PHE | VAL | ||||
29 | VAL | CYS | TRP | LEU | PRO | TYR | HIS | VAL | ARG | ARG | ||||
30 | LEU | MET | PHE | VAL | TYR | ILE | SER | ASP | GLU | GLN | ||||
31 | TRP | THR | THR | ALA | LEU | PHE | ASP | PHE | TYR | HIS | ||||
32 | TYR | PHE | TYR | MET | LEU | SER | ASN | ALA | LEU | VAL | ||||
33 | TYR | VAL | SER | ALA | ALA | ILE | ASN | PRO | ILE | LEU | ||||
34 | TYR | ASN | LEU | VAL | SER | ALA | ASN | PHE | ARG | GLN | ||||
35 | VAL | PHE | LEU | SER | THR | LEU | ALA | SER | LEU | SER | ||||
36 | PRO | GLY | TRP | ARG | HIS | ARG | ARG | LYS | LYS | ARG | ||||
37 | PRO | THR | PHE | SER | ARG | LYS | PRO | ASN | SER | VAL | ||||
38 | SER | SER | ASN | HIS | ALA | PHE | SER | THR | ALA | SER | ||||
39 | GLY | LEU | ASN | ASP | ILE | PHE | GLU | ALA | GLN | LYS | ||||
40 | ILE | GLU | TRP | HIS | GLU | GLY | SER | GLY | LEU | GLU | ||||
41 | VAL | LEU | PHE | GLN |
Entity 2, NT8-13 6 residues - 817 Da.
1 | ARG | ARG | PRO | TYR | ILE | LEU |
Entity 3, Gaiq 357 residues - 40611.26 Da.
G alpha i with the six C-terminal residues from G alpha q (KEYNLV)
1 | GLY | PRO | GLY | SER | GLY | CYS | THR | LEU | SER | ALA | ||||
2 | GLU | ASP | LYS | ALA | ALA | VAL | GLU | ARG | SER | LYS | ||||
3 | MET | ILE | ASP | ARG | ASN | LEU | ARG | GLU | ASP | GLY | ||||
4 | GLU | LYS | ALA | ALA | ARG | GLU | VAL | LYS | LEU | LEU | ||||
5 | LEU | LEU | GLY | ALA | GLY | GLU | SER | GLY | LYS | SER | ||||
6 | THR | ILE | VAL | LYS | GLN | MET | LYS | ILE | ILE | HIS | ||||
7 | GLU | ALA | GLY | TYR | SER | GLU | GLU | GLU | CYS | LYS | ||||
8 | GLN | TYR | LYS | ALA | VAL | VAL | TYR | SER | ASN | THR | ||||
9 | ILE | GLN | SER | ILE | ILE | ALA | ILE | ILE | ARG | ALA | ||||
10 | MET | GLY | ARG | LEU | LYS | ILE | ASP | PHE | GLY | ASP | ||||
11 | SER | ALA | ARG | ALA | ASP | ASP | ALA | ARG | GLN | LEU | ||||
12 | PHE | VAL | LEU | ALA | GLY | ALA | ALA | GLU | GLU | GLY | ||||
13 | PHE | MET | THR | ALA | GLU | LEU | ALA | GLY | VAL | ILE | ||||
14 | LYS | ARG | LEU | TRP | LYS | ASP | SER | GLY | VAL | GLN | ||||
15 | ALA | CYS | PHE | ASN | ARG | SER | ARG | GLU | TYR | GLN | ||||
16 | LEU | ASN | ASP | SER | ALA | ALA | TYR | TYR | LEU | ASN | ||||
17 | ASP | LEU | ASP | ARG | ILE | ALA | GLN | PRO | ASN | TYR | ||||
18 | ILE | PRO | THR | GLN | GLN | ASP | VAL | LEU | ARG | THR | ||||
19 | ARG | VAL | LYS | THR | THR | GLY | ILE | VAL | GLU | THR | ||||
20 | HIS | PHE | THR | PHE | LYS | ASP | LEU | HIS | PHE | LYS | ||||
21 | MET | PHE | ASP | VAL | GLY | GLY | GLN | ARG | SER | GLU | ||||
22 | ARG | LYS | LYS | TRP | ILE | HIS | CYS | PHE | GLU | GLY | ||||
23 | VAL | THR | ALA | ILE | ILE | PHE | CYS | VAL | ALA | LEU | ||||
24 | SER | ASP | TYR | ASP | LEU | VAL | LEU | ALA | GLU | ASP | ||||
25 | GLU | GLU | MET | ASN | ARG | MET | HIS | GLU | SER | MET | ||||
26 | LYS | LEU | PHE | ASP | SER | ILE | CYS | ASN | ASN | LYS | ||||
27 | TRP | PHE | THR | ASP | THR | SER | ILE | ILE | LEU | PHE | ||||
28 | LEU | ASN | LYS | LYS | ASP | LEU | PHE | GLU | GLU | LYS | ||||
29 | ILE | LYS | LYS | SER | PRO | LEU | THR | ILE | CYS | TYR | ||||
30 | PRO | GLU | TYR | ALA | GLY | SER | ASN | THR | TYR | GLU | ||||
31 | GLU | ALA | ALA | ALA | TYR | ILE | GLN | CYS | GLN | PHE | ||||
32 | GLU | ASP | LEU | ASN | LYS | ARG | LYS | ASP | THR | LYS | ||||
33 | GLU | ILE | TYR | THR | HIS | PHE | THR | CYS | ALA | THR | ||||
34 | ASP | THR | LYS | ASN | VAL | GLN | PHE | VAL | PHE | ASP | ||||
35 | ALA | VAL | THR | ASP | VAL | ILE | ILE | LYS | ASN | ASN | ||||
36 | LEU | LYS | GLU | TYR | ASN | LEU | VAL |
Entity 4, PIP2 - Formula weight is not available
sample_1: enNTS1DM4, [13CH3-methionine], 64 uM; potassium phosphate 50 mM; NaCl 100 mM; DSS 20 uM; DDM 0.05%; NT8-13 500 uM; G alpha i/q chimera 145 uM; 08:0 PI(4,5)P2 130 uM
sample_conditions_1: ionic strength: 150 mM; pH: 7.4; pressure: 1 atm; temperature: 298 K
Name | Sample | Sample state | Sample conditions |
---|---|---|---|
2D 1H-13C HMQC | sample_1 | isotropic | sample_conditions_1 |
SPARKY - chemical shift assignment, data analysis
TOPSPIN - data collection
qMDD - processing